Your browser doesn't support javascript.
loading
Riluzole promotes neurological function recovery and inhibits damage extension in rats following spinal cord injury: a meta-analysis and systematic review.
Zhou, Long-Yun; Tian, Zi-Rui; Yao, Min; Chen, Xu-Qing; Song, Yong-Jia; Ye, Jie; Yi, Nan-Xing; Cui, Xue-Jun; Wang, Yong-Jun.
Afiliación
  • Zhou LY; Spine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Tian ZR; Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Yao M; Rehabilitation Medicine College, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Chen XQ; Spine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Song YJ; Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Ye J; Spine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Yi NX; Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Cui XJ; Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China.
  • Wang YJ; Spine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Neurochem ; 150(1): 6-27, 2019 07.
Article en En | MEDLINE | ID: mdl-30786027
ABSTRACT
Spinal cord injury (SCI) is a devastating condition that has few treatment options. Riluzole, a sodium channel blocker used to treat amyotrophic lateral sclerosis, has been initially trialed in human SCI. We performed a systematic review to critically assess the efficacy of riluzole in locomotor recovery and damage extension in SCI rat models, and the potential for clinical translation. PubMed, Embase, Cochrane Library, and Chinese databases were searched from their inception date to March 2018. Two reviewers independently selected animal studies that evaluated neurological recovery and lesion area following riluzole treatment in SCI rat models, extracted data and assessed methodological quality. Pairwise meta-analysis, subgroup analysis, and network meta-analysis were performed to assess the effects of riluzole on SCI. Ten eligible studies were included. Two studies had high methodological quality. Overall, the Basso, Beattie, and Bresnahan scores were increased in riluzole-treated animals versus controls, and effect sizes showed a gradual increase from the 1st (five studies, n = 104, mean difference = 1.24, 95% CI = 0.11 to 2.37, p = 0.03) to 6th week after treatment (five studies, n = 120, mean difference = 2.34, 95% CI = 1.26 to 3.42, p < 0.0001). Riluzole was associated with improved outcomes in the inclined plane test and the tissue preservation area. Subgroup analyses suggested an association of locomotor recovery with riluzole dose. Network meta-analysis showed that 5 mg/kg riluzole exhibited greater protection than 2.5 and 8 mg/kg riluzole. Collectively, this review suggests that riluzole has a protective effect on SCI, with good safety and a clear mechanism of action and may be suitable for future clinical trials or applications. However, animal results should be interpreted with caution given the known limitations in animal experimental design and methodological quality.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Médula Espinal / Traumatismos de la Médula Espinal / Fármacos Neuroprotectores / Riluzol / Recuperación de la Función Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals Idioma: En Revista: J Neurochem Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Médula Espinal / Traumatismos de la Médula Espinal / Fármacos Neuroprotectores / Riluzol / Recuperación de la Función Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals Idioma: En Revista: J Neurochem Año: 2019 Tipo del documento: Article País de afiliación: China